UnitedHealth Group Expands Coverage for Guardant Health’s Shield Blood Test, Increasing Access to Colorectal Cancer Screening
Guardant Health, a leader in precision oncology, has announced that its Shield™ blood test for colorectal cancer (CRC) screening is now covered for eligible members of UnitedHealth Group (UHG). The policy marks a significant milestone for both the company and colorectal cancer prevention efforts, as UnitedHealth Group becomes the first major commercial health insurer to provide broad coverage for the FDA-approved blood-based screening test for average-risk adults aged 45 and older.
The coverage expansion substantially increases access to Shield, giving millions of eligible Americans another screening option that can be completed with a simple blood draw during a routine physician visit. The decision comes at a time when healthcare professionals continue to report increasing rates of colorectal cancer among younger adults and emphasize the importance of early detection to improve patient outcomes.
A Major Milestone in Commercial Coverage
The newly announced coverage represents a major commercial achievement for Guardant Health as it continues to expand adoption of its innovative blood-based cancer screening technology.
UnitedHealth Group is one of the largest health insurers in the United States, providing healthcare coverage to approximately 40 million people through a wide range of commercial and government-sponsored insurance programs.
The updated coverage policy applies to eligible individuals enrolled in:
- Employer-sponsored health plans
- Individual health insurance plans
- Medicare Advantage plans
- Medicare supplemental coverage
Under the revised policy, adults 45 years of age and older who are considered at average risk for colorectal cancer may now receive insurance coverage for the Shield blood test as part of routine colorectal cancer screening.
The announcement positions UnitedHealth Group as the first major commercial insurer to reimburse the FDA-approved blood test, potentially encouraging additional private insurers to evaluate similar coverage decisions in the future.
Expanding Access to Colorectal Cancer Screening
Guardant Health emphasized that the expanded insurance coverage will significantly improve access to colorectal cancer screening by removing financial barriers for millions of eligible individuals.
According to the company, more than 100 million Americans now have access to the Shield blood test through a combination of commercial insurance coverage and other reimbursement pathways.
The latest expansion is particularly important because colorectal cancer remains one of the most preventable forms of cancer when detected early through routine screening.
Despite well-established screening recommendations, many eligible adults continue to delay or avoid screening due to concerns about traditional testing methods.
By providing a less invasive option that fits easily into routine healthcare visits, Guardant Health hopes to encourage higher participation rates among individuals who may otherwise postpone screening.
Addressing Rising Rates of Colorectal Cancer
The announcement comes as healthcare providers continue to express growing concern about the increasing incidence of colorectal cancer among younger adults.
Although colorectal cancer has historically been associated with older populations, recent research has shown rising diagnosis rates among adults under the age of 65.
Even more concerning, colorectal cancer has become the leading cause of cancer-related death among adults younger than 50, underscoring the importance of identifying disease at its earliest and most treatable stages.
These changing epidemiological trends prompted leading medical organizations in recent years to lower the recommended age for average-risk colorectal cancer screening from 50 to 45 years.
The updated UnitedHealth Group coverage aligns with these modern screening recommendations by providing eligible adults beginning at age 45 access to the Shield blood test.
A Blood-Based Alternative to Traditional Screening
Shield represents a different approach to colorectal cancer screening compared with traditional screening methods.
Unlike stool-based screening tests or colonoscopy procedures, Shield requires only a standard blood sample collected during a routine healthcare appointment.
The blood sample is then analyzed using Guardant Health’s proprietary technology to identify molecular signals associated with colorectal cancer.
The convenience of a blood draw may reduce many of the barriers that discourage patients from participating in routine screening.
Traditional colorectal cancer screening methods often involve bowel preparation, collection of stool samples, scheduling specialized procedures, or taking time away from work.
A simple blood test performed during a routine physician visit offers patients an additional screening option that may improve compliance with recommended screening guidelines.
First and Only FDA-Approved Blood Test
Guardant Health noted that Shield is currently the first and only blood test approved by the U.S. Food and Drug Administration (FDA) for primary colorectal cancer screening in average-risk adults aged 45 years and older.
The FDA approval represented an important advancement in cancer screening by recognizing blood-based testing as an approved option for eligible patients.
The approval followed extensive clinical evaluation demonstrating the test’s ability to detect colorectal cancer in average-risk individuals.
The availability of an FDA-approved blood test expands the range of screening choices available to patients and healthcare providers, allowing physicians to better tailor screening approaches based on individual patient preferences and circumstances.
Strong Clinical Evidence Supports Shield
Guardant Health highlighted the extensive body of clinical evidence supporting Shield’s performance.
The company stated that clinical validation data, along with real-world evidence evaluating the blood test, have been published in the New England Journal of Medicine (NEJM), one of the world’s most respected peer-reviewed medical journals.
Publication in a leading medical journal reflects the scientific rigor of the studies evaluating the test and provides physicians with independently reviewed evidence supporting its clinical use.
Clinical performance data have played an important role in expanding physician confidence in blood-based colorectal cancer screening technologies.
Recognition by Leading Medical Organizations
Beyond FDA approval, Shield has also received recognition from major professional medical organizations.
According to Guardant Health, Shield is currently the only FDA-approved blood-based colorectal cancer screening test included in both:
- American Cancer Society (ACS) colorectal cancer screening guidelines
- National Comprehensive Cancer Network (NCCN) colorectal cancer screening guidelines
Inclusion in these nationally recognized guidelines provides important validation for physicians considering screening options for average-risk patients.
Guideline recommendations are frequently used by healthcare providers, insurers, and policymakers when determining appropriate standards of care and insurance reimbursement decisions.
The inclusion of Shield in both guideline frameworks likely contributed to broader payer adoption.
Executive Perspective
Guardant Health Co-Chief Executive Officer AmirAli Talasaz described the UnitedHealth Group coverage decision as an important milestone in expanding patient access.
He noted that more than 100 million Americans now have access to the Shield blood test and emphasized that the latest coverage expansion significantly broadens availability among adults aged 45 years and older.
Talasaz also highlighted the growing concern surrounding increasing colorectal cancer rates in younger populations, stating that expanding reimbursement through the nation’s largest commercial health insurer represents an important step toward making routine colorectal cancer screening more accessible.
The company believes broader insurance coverage will help encourage earlier screening while supporting nationwide efforts to improve early cancer detection.
Importance of Early Detection
Medical experts consistently emphasize that early detection remains one of the most effective strategies for reducing colorectal cancer mortality.
When identified in its earliest stages, colorectal cancer is often highly treatable, with significantly improved survival outcomes compared with advanced disease.
Routine screening enables physicians to identify cancer before symptoms develop and, in many cases, detect precancerous abnormalities that can be treated before progressing into invasive cancer.
Unfortunately, screening participation remains below recommended levels in many populations.
By introducing a convenient blood-based screening option covered by a major commercial insurer, Guardant Health hopes to reduce screening gaps and encourage more eligible adults to participate in preventive care.
Expanding Commercial Adoption
Insurance reimbursement is often one of the most important factors influencing adoption of new medical technologies.
Healthcare providers are generally more likely to recommend newly approved diagnostic tests when insurance coverage reduces financial barriers for patients.
Similarly, patients are more likely to undergo recommended screening when tests are covered by their health plans.
The UnitedHealth Group policy therefore represents not only increased patient access but also an important commercial milestone for Guardant Health as it continues expanding adoption of Shield across the U.S. healthcare system.
The company may also benefit from additional private insurers reviewing their own coverage policies as evidence supporting blood-based colorectal cancer screening continues to grow.
The expansion of UnitedHealth Group’s coverage for Guardant Health’s Shield blood test represents a significant advancement in colorectal cancer screening accessibility. By extending insurance coverage to eligible adults aged 45 and older, the policy supports earlier detection efforts at a time when colorectal cancer rates are rising among younger populations.
As the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults, Shield offers patients a convenient alternative to traditional screening methods while maintaining strong clinical support through published evidence and inclusion in leading medical guidelines. With access now reaching more than 100 million Americans, the latest coverage decision strengthens Guardant Health’s commercial presence and reinforces the growing role of blood-based diagnostics in preventive cancer care.
Source link: https://investors.guardanthealth.com/
